Differential effects of CB1 and CB2 agonists on cAMP levels and MAP kinase activation in human peripheral blood mononuclear cells.
Makda
A A
AA
Yamanouchi Research Institute, Oxford.
Elmore
M A
MA
Hill
M E
ME
Stamps
A
A
Tejura
S
S
Finnen
M J
MJ
D000577:Amides; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism*; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism*; D013759:Dronabinol / Q000494:pharmacology*; D063388:Endocannabinoids; D004789:Enzyme Activation; D004983:Ethanolamines; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008214:Lymphocytes / Q000187:drug effects / Q000502:physiology*; D010169:Palmitic Acids / Q000494:pharmacology; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects
D000577:Amides; D063388:Endocannabinoids; D004983:Ethanolamines; D010169:Palmitic Acids; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C005958:palmidrol; D013759:Dronabinol; D000242:Cyclic AMP; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D007545:Isoproterenol